Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amedisys (AMED) Q1 Earnings Top Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 16.28% and 0.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable

For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.

Here's Why You Should Retain Amedisys (AMED) Stock for Now

Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.

Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips

Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.

Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys (AMED) Faces Macro Challenges, Margin Pressure

The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.

Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?

Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.

Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut

Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.

Amedisys (AMED) Misses Q3 Earnings and Revenue Estimates

Amedisys (AMED) delivered earnings and revenue surprises of -7.26% and 3.41%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Amedisys (AMED) Stock Options

Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.

Debanjana Dey headshot

3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.

Here's Why Investors Should Retain Amedisys (AMED) Stock for Now

Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.

Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down

Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.

Amedisys (AMED) Q2 Earnings Beat Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 19.51% and 4.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for

Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care

Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.

Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range

Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.

Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?

Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.

Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Amedisys (AMED) Stock for Now

Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.